Senolytic therapies should enter clinical trials for age-related diseases

Combining NAD+ boosters with senolytics shows enough preclinical promise to justify large-scale human trials.

From the articleNAD+, Senolytics, or Pyruvate for Healthy Aging?Also in Unlocking Human Longevity: Mayo Clinic Scientists Fuse NAD Boosters and Senolytics